PreveCeutical Medical Inc.
PRVCF
$0.025
-$0.0005-1.96%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 430.27% | -44.80% | |||
| Depreciation & Amortization | 22.22% | -5.26% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 358.08% | -40.26% | |||
| Operating Income | -358.08% | 40.26% | |||
| Income Before Tax | -208.29% | 29.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -208.29% | 29.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -208.29% | 29.89% | |||
| EBIT | -358.08% | 40.26% | |||
| EBITDA | -364.65% | 40.72% | |||
| EPS Basic | -233.33% | 40.00% | |||
| Normalized Basic EPS | -200.00% | 33.33% | |||
| EPS Diluted | -233.33% | 40.00% | |||
| Normalized Diluted EPS | -200.00% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | -0.15% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||